Literature DB >> 7180560

Pneumoencephalographic evidence of brain atrophy in acute and chronic schizophrenic patients.

J O Haug.   

Abstract

Pneumoencephalography (PEG) was carried out in 50 patients of both sexes consecutively discharged from a psychiatric department with a diagnosis of acute schizophrenia. At clinical follow-up with a mean observation time of 8 years the diagnosis was verified in 38 patients, while 12 were considered to have had a reactive psychosis. The PEG findings and clinical findings in these two groups are compared, and compared to corresponding findings in 101 chronic schizophrenics previously studied with the same method. Linear measurements were used in estimating the size of the ventricular system, which was safely within normal limits in all but three of the 50 patients. Mean ventricular size did not differ significantly in the two groups of acute psychoses. No case of cortical atrophy was found. More than half of the chronic schizophrenics had abnormal PEG's, the typical finding being a bilateral enlargement of the ventricular system. The mean size of all parts of the ventricular system was significantly higher than in the acute schizophrenics. A close correlation was found between mental deterioration and ventricular enlargement. The most reasonable explanation of these findings is that schizophrenia is an inborn error of metabolism, disturbing normal brain function and in the long run leading to degenerative changes of the nervous tissue.

Entities:  

Mesh:

Year:  1982        PMID: 7180560     DOI: 10.1111/j.1600-0447.1982.tb06719.x

Source DB:  PubMed          Journal:  Acta Psychiatr Scand        ISSN: 0001-690X            Impact factor:   6.392


  10 in total

Review 1.  Very poor outcome schizophrenia: clinical and neuroimaging aspects.

Authors:  Serge A Mitelman; Monte S Buchsbaum
Journal:  Int Rev Psychiatry       Date:  2007-08

Review 2.  The concept of progressive brain change in schizophrenia: implications for understanding schizophrenia.

Authors:  Lynn E DeLisi
Journal:  Schizophr Bull       Date:  2008-02-08       Impact factor: 9.306

3.  What a Clinician Should Know About the Neurobiology of Schizophrenia: A Historical Perspective to Current Understanding.

Authors:  Lynn E DeLisi
Journal:  Focus (Am Psychiatr Publ)       Date:  2020-11-05

4.  A quantitative magnetic resonance imaging study of patients with schizophrenia.

Authors:  Y Kawasaki; Y Maeda; K Urata; M Higashima; N Yamaguchi; M Suzuki; T Takashima; Y Ide
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  1993       Impact factor: 5.270

Review 5.  History of the Concept of Disconnectivity in Schizophrenia.

Authors:  Joseph T Coyle; Darrick T Balu; Matthew D Puhl; Glenn T Konopaske
Journal:  Harv Rev Psychiatry       Date:  2016 Mar-Apr       Impact factor: 3.732

6.  The diencephalon in schizophrenia: evidence for reduced thickness of the periventricular grey matter.

Authors:  A Lesch; B Bogerts
Journal:  Eur Arch Psychiatry Neurol Sci       Date:  1984

7.  Morphological alterations of the pyramidal and stellate cells of the visual cortex in schizophrenia.

Authors:  Ioannis Mavroudis; Foivos Petrides; Dimitrios Kazis; Symela Chatzikonstantinou; Eleni Karantali; Alin Ciobica; Alin-Constantin Iordache; Romeo Dobrin; Constantin Trus; Samuel Njau; Vasiliki Costa; Stavros Baloyannis
Journal:  Exp Ther Med       Date:  2021-04-22       Impact factor: 2.447

Review 8.  Understanding structural brain changes in schizophrenia.

Authors:  Lynn E DeLisi; Kamila U Szulc; Hilary C Bertisch; Magda Majcher; Kyle Brown
Journal:  Dialogues Clin Neurosci       Date:  2006       Impact factor: 5.986

Review 9.  Structural neuroimaging in schizophrenia: from methods to insights to treatments.

Authors:  Martha E Shenton; Thomas J Whitford; Marek Kubicki
Journal:  Dialogues Clin Neurosci       Date:  2010       Impact factor: 5.986

Review 10.  The myth of schizophrenia as a progressive brain disease.

Authors:  Robert B Zipursky; Thomas J Reilly; Robin M Murray
Journal:  Schizophr Bull       Date:  2012-11-20       Impact factor: 9.306

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.